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limited data on settings, use of specialised centres and inappro-
priate gender balance. Relevant, potentially usable systematic
reviews were identiﬁed for 27 (54%) of the economic evalua-
tions in the sample, although none had been used. The use of
data from systematic reviews would change the size of reported
cost-effectiveness ratios. CONCLUSIONS: These ﬁndings
suggest that critical appraisal of the clinical data underlying eco-
nomic evaluations is needed before they are used in health care
decision-making. Best available clinical evidence is not being
utilised and further research is indicated to quantify the impli-
cations of using poor quality, or selective effectiveness data in
economic evaluations.
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OBJECTIVES: In recent years, a number of health economists
have introduced the potential of using portfolio theory as a basis
for resource allocation in health. Portfolio theory is concerned
with the optimal investment strategy, based on both return and
risk, and demonstrates the potential beneﬁts from pooling dif-
ferent investments into a single portfolio. Furthermore, portfo-
lio theory can be modiﬁed to allow for synergies between
interventions. Given that in public health we often need to imple-
ment multiple health care interventions with a single, ﬁxed health
budget, portfolio theory is of beneﬁt both theoretically, and prac-
tically. METHODS: Using both theoretical and simulation mod-
elling this paper demonstrates the importance of using a modiﬁed
portfolio theory framework when evaluating a number of health
interventions from the perspective of a representative individual.
This is done by varying the level of correlation and synergy
between two programs and focusing on stylised portfolio con-
sisting of equal resource shares of each of the programs.
RESULTS: The paper demonstrates the importance of taking a
portfolio approach in considering the resource allocations made
in the presence of risk. Risk can be reduced by combining pro-
grams, given that they are not perfectly correlated. If one allows
for non-linearities through the inclusion of synergies, then port-
folio theory is important for those who are even risk neutral.
CONCLUSIONS: While portfolio analysis in health care is the-
oretically appealing, there are a number of pragmatic reasons for
using it. Portfolio theory emphasizes the trade-offs required by
a ﬁxed budget and the importance of taking a global perspec-
tive, rather than piecemeal one, in the evaluation of health care
interventions. A number of limitations in the portfolio approach
exist, but many of these concerns are found in all forms of eco-
nomic evaluation in health care.
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PMC8 OBJECTIVES: In 2002, the three Local Health Authorities
(LHA’s)of Bologna province (Emilia-Romagna region, Italy)
began an outreach visits program aimed at modifying NHS pre-
scriptions of speciﬁc drugs through evidence-based information
packages and prescribing feedback. Aim of this study is to eval-
uate the impact of the pharmacist’s outreach visits program com-
paring Coxib prescribing volumes between the intervention and
three control LHA’s of the same region (Parma, Ferrara, Imola).
METHODS: Prescribing databases were available for both inter-
vention and control LHA’s from october 2000 to october 2003;
time series data of Coxib monthly consumption were expressed
in DDD’s. For each LHA, 2 time series were considered: the ﬁrst,
based on observed data, plots the real DDD’s trend over 36
months; the second, expected, ﬁts the time series until the inter-
vention date—november 2002—and subsequently forecasts the
forthcoming 12 months estimating DDDs under the hypothesis
of no intervention. Data analysis was performed using SAS/ETS
module(Estimating Time Series) of SAS System: expected time
series were computed with ARIMA intervention modelling.
RESULTS: Since november 2002, all monthly DDD’s observed
in the intervention LHA’s lie under the lower 95% conﬁdence
interval of the estimated DDD’s forecasted by the model; vice
versa, since November 2002, all montly DDD’s observed in the
control LHA’s lie within the 95% conﬁdence interval of the fore-
casted data; this results show a signiﬁcant reduction in prescrib-
ing volumes for the intervention LHA’s. CONCLUSIONS: Use
of ARIMA intervention modelling for drug prescriptions time
series may be a useful and easy to understand way of assessing
the impact of drug information programs in terms of prescrib-
ing modiﬁcations.
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OBJECTIVES: In 2005, the Medicare Prescription Drug,
Improvement and Modernization Act (MMA) of 2003 requires
payment for drugs administered in the physician’s ofﬁce at a new
rate of average sales price plus 6%. This study provides a con-
ceptual view of the change and suggests a conceptual modiﬁca-
tion. METHODS: When the MMA imposed the new drug
payment method, it also increased payment for drug adminis-
tration. We postulate these relative weights used for the fee
increases are diluted because they are specialty-speciﬁc rather
than speciﬁc to practice type. This dilution defeats the original
purpose of resource-based practice expenses. EVALUATION OF
RESULTS: Resource-based methods for 2005 related to drugs
and their administration were collected and deconstructed. Leg-
islative rationales for the new drug payment method and for the
differential in transitional procedure payments (32% add-on in
2005 versus 3% add-on in 2006) were identiﬁed. Computations
utilizing the new methods were evaluated for indications of
resource-based level of effort applications. CONCLUSIONS:
Because the drug payment method is new and untested, we esti-
mate a 2-year implementation period is needed before evalua-
tions can occur. We also believe the present formula for indirect
cost allocation within a specialty does not sufﬁciently distinguish
between a practice that provides these high-technology drugs
(high resource consumption) versus other practices that do not
(lower resource consumption). We propose a new add-on com-
ponent within the practice expense formula. This new compo-
nent provides the practice that administers high-technology
drugs with a higher indirect cost weight than a practice that does
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